An orally available inhibitor of SGLT1 and SGLT2 (IC50s = 36 and 1.8 nM, respectively, for human isoforms in vitro); improves glycemic control in nonobese diabetes prone mice with type 1 diabetes and in patients with type 2 diabetes in a randomized, placebo-controlled clinical trial.